Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

  • Name

    ICON Public Limited Company

  • CEO

    Dr. Steven A. Cutler MBA, Ph.D.

  • Website

    www.iconplc.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1990

Profile

  • Market Cap

    $25.51B

  • EV

    $28.62B

  • Shares Out

    82.82M

  • Revenue

    $8,331.89M

  • Employees

    41,100

Margins

  • Gross

    29.74%

  • EBITDA

    20.64%

  • Operating

    13.5%

  • Pre-Tax

    9.05%

  • Net

    8.57%

  • FCF

    14.19%

Returns (5Yr Avg)

  • ROA

    6.57%

  • ROTA

    15.69%

  • ROE

    12.14%

  • ROCE

    13.05%

  • ROIC

    9.94%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $365.4

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $506.55M

  • Net Debt

    $3,113.13M

  • Debt/Equity

    0.38

  • EBIT/Interest

    3.78

Growth (CAGR)

  • Rev 3Yr

    37.7%

  • Rev 5Yr

    25.24%

  • Rev 10Yr

    19.43%

  • Dil EPS 3Yr

    7.87%

  • Dil EPS 5Yr

    5.87%

  • Dil EPS 10Yr

    14.63%

  • Rev Fwd 2Yr

    6.53%

  • EBITDA Fwd 2Yr

    9.43%

  • EPS Fwd 2Yr

    15.94%

  • EPS LT Growth Est

    15.41%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:ICLR